Blog and News

" is a politically neutral grassroots coalition of physicians.  Use of any politically partisan terms does not reflect the position of  We do encourage our speakers to express how they feel and we post articles based on their informative content only.  Any politically partisan language used does not reflect the group as a whole.  Specific party or political allegiances and opposition are not our intent.  The goal of D4PC is only to advocate for effective and responsible health care reform."

The Limits of Comparative Effectiveness Research

Wednesday, July 13, 2011

Tomas J. Philipson and Eric Sun, respectively of the University of Chicago and Stanford University, have produced a report for the Manhattan Institute entitled "Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research." Their report explains the fallacy of the over-reliance by President Obama and PPACA on comparative effectiveness research (CER) to reduce costs. The President's logic suggests that if, on average, the "blue pill" is as effective for the average patient as the "red pill" and cheaper that the correct course of treatment should be the blue pill. The problem is, as the Executive Summary for Philipson and Sun's report states, "the average patient is not the same as any particular individual patient. Declaring a treatment most effective based on an average is a medical and an economic error, for two reasons."

Read More... 
Go Back

Recent Posts